Hydrophilic Sequence-Defined Cross-Linkers for Antibody-Drug Conjugates

被引：16

作者：

Walker, Joshua A. ^{[1
]}

Sorkin, Michelle R. ^{[1
]}

Ledesma, Francis ^{[1
]}

Kabaria, Sneha R. ^{[1
]}

Barfield, Robyn M. ^{[2
]}

Rabuka, David ^{[2
]}

Alabi, Christopher A. ^{[1
]}

机构：

[1] Cornell Univ, Robert Frederick Smith Sch Chem & Biomol Engn, 113 Ho Plaza, Ithaca, NY 14850 USA

[2] Catalent Biol, 5703 Hollis St, Emeryville, CA 94608 USA

来源：

BIOCONJUGATE CHEMISTRY | 2019年 / 30卷 / 11期

关键词：

PHARMACOKINETICS; SITE; GENERATION; EFFICACY;

D O I：

10.1021/acs.bioconjchem.9b00713

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Antibody-drug conjugates (ADCs) are an established modality for the tissue-specific delivery of chemotherapeutics. However, due to the hydrophobic nature of many cytotoxic payloads, challenges remain in developing chemically stable ADCs with high drug loading. In previous studies, payload structure, unique stimuli-responsive chemistries, and PEGylated cross-linkers have been used to decrease ADC hydrophobicity. In this work, we investigate the effect of a new parameter, cross-linker sequence. A support-free synthesis of PEGylated, sequence-defined cross-linkers was developed and applied to the synthesis of three constitutionally isomeric ADCs containing PEG side chains and a monomethyl auristatin E payload. Placement of PEG side chains distally from the payload was found to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency. This work establishes a versatile method for synthesizing multifunctional cross-linkers and identifies cross-linker sequence as a new handle for modulating the performance of ADCs.

引用

页码：2982 / 2988

页数：7

共 35 条

[1] Hydrazino-Pictet-Spengler Ligation as a Biocompatible Method for the Generation of Stable Protein Conjugates [J].

Agarwal, Paresh ;

Kudirka, Romas ;

Albers, Aaron E. ;

Barfield, Robyn M. ;

de Hart, Gregory W. ;

Drake, Penelope M. ;

Jones, Lesley C. ;

Rabuka, David .

BIOCONJUGATE CHEMISTRY, 2013, 24 (06) :846-851

[2] Strategies and challenges for the next generation of antibody drug conjugates [J].

Beck, Alain ;

Goetsch, Liliane ;

Dumontet, Charles ;

Corvaia, Nathalie .

NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (05) :315-337

[3] Investigation into Temperature-Induced Aggregation of an Antibody Drug Conjugate [J].

Beckley, Nia S. ;

Lazzareschi, Kathlyn P. ;

Chih, Hung-Wei ;

Sharma, Vikas K. ;

Flores, Heather L. .

BIOCONJUGATE CHEMISTRY, 2013, 24 (10) :1674-1683

[4] In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios [J].

Bryant, Penny ;

Pabst, Martin ;

Badescu, George ;

Bird, Matthew ;

McDowell, William ;

Jamieson, Estera ;

Swierkosz, Julia ;

Jurlewicz, Kosma ;

Tommasi, Rita ;

Henseleit, Korinna ;

Sheng, XiaoBo ;

Camper, Nicolas ;

Manin, Anais ;

Kozakowska, Katarzyna ;

Peciak, Karolina ;

Laurine, Emmanuelle ;

Grygorash, Ruslan ;

Kyle, Andrew ;

Morris, David ;

Parekh, Vimal ;

Abhilash, Amrita ;

Choi, Ji-won ;

Edwards, Jeff ;

Frigerio, Mark ;

Baker, Matthew P. ;

Godwin, Antony .

MOLECULAR PHARMACEUTICS, 2015, 12 (06) :1872-1879

[5] Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates [J].

Buecheler, Jakob W. ;

Winzer, Matthias ;

Tonillo, Jason ;

Weber, Christian ;

Gieseler, Henning .

MOLECULAR PHARMACEUTICS, 2018, 15 (07) :2656-2664

[6] Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates [J].

Burke, Patrick J. ;

Hamilton, Joseph Z. ;

Jeffrey, Scott C. ;

Hunter, Joshua H. ;

Doronina, Svetlana O. ;

Okeley, Nicole M. ;

Miyamoto, Jamie B. ;

Anderson, Martha E. ;

Stone, Ivan J. ;

Ulrich, Michelle L. ;

Simmons, Jessica K. ;

McKinney, Erica E. ;

Senter, Peter D. ;

Lyon, Robert P. .

MOLECULAR CANCER THERAPEUTICS, 2017, 16 (01) :116-123

[7] Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates [J].

Burke, Patrick J. ;

Hamilton, Joseph Z. ;

Pires, Thomas A. ;

Setter, Jocelyn R. ;

Hunter, Joshua H. ;

Cochran, Julia H. ;

Waight, Andrew B. ;

Gordon, Kristine A. ;

Toki, Brian E. ;

Emmerton, Kim K. ;

Zeng, Weiping ;

Stone, Ivan J. ;

Senter, Peter D. ;

Lyon, Robert P. ;

Jeffrey, Scott C. .

MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) :938-945

[8] Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates [J].

Donaghy, Heather .

MABS, 2016, 8 (04) :659-671

[9] Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma [J].

Dornan, David ;

Bennett, Fiona ;

Chen, Yvonne ;

Dennis, Mark ;

Eaton, Dan ;

Elkins, Kristi ;

French, Dorothy ;

Go, Mary Ann T. ;

Jack, Andrew ;

Junutula, Jagath R. ;

Koeppen, Hartmut ;

Lau, Jeffrey ;

McBride, Jacqueline ;

Rawstron, Andy ;

Shi, Xiaoyan ;

Yu, Nancy ;

Yu, Shang-Fan ;

Yue, Peng ;

Zheng, Bing ;

Ebens, Allen ;

Polson, Andrew G. .

BLOOD, 2009, 114 (13) :2721-2729

[10] Development of potent monoclonal antibody auristatin conjugates for cancer therapy [J].

Doronina, SO ;

Toki, BE ;

Torgov, MY ;

Mendelsohn, BA ;

Cerveny, CG ;

Chace, DF ;

DeBlanc, RL ;

Gearing, RP ;

Bovee, TD ;

Siegall, CB ;

Francisco, JA ;

Wahl, AF ;

Meyer, DL ;

Senter, PD .

NATURE BIOTECHNOLOGY, 2003, 21 (07) :778-784

← 1 2 3 4 →